| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Tizoxanide, a thiazolide anti-infective, is an active metabolite of Nitazoxanide (also known as NTZ; NSC 697855), which is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent with IC50 for canine influenza virus ranges from 0.17 to 0.21 μM. Tizoxanide is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.
| Targets |
Tizoxanide (TIZ) has potent inhibition of both HBV and HCV replication with values EC50 of 0.46μM and 0.15 μM, respectively
|
||
|---|---|---|---|
| ln Vitro |
Tizoxanide is the active metabolite of Nitazoxanide, which is a thiazolide anti-infective compound against anaerobic bacteria, protozoa, and a range of viruses. IC50 value: Target: Antiviral agent in vitro: Tizoxanide inhibited virus replication of all CIVs with 50% and 90% inhibitory concentrations ranging from 0.17 to 0.21 μM and from 0.60 to 0.76 μM, respectively. Nitazoxanide and its primary metabolite, tizoxanide, inhibit hepatitis C virus (HCV) replication in HCV replicon systems. Interestingly, serial passage in nitazoxanide or tizoxanide resulted in increased sensitivity to alpha interferon 2b: EC(50)s and EC(90)s were reduced three- and eightfold, respectively.
|
||
| ln Vivo |
Nitazoxanide is partially effective at reducing the parasite burden in a gnotobiotic piglet diarrhea model when given orally for 11 days at 250 mg/kg/day but not at 125 mg/kg/day. Nitazoxanide induces a drug-related diarrhea in piglets that might have influenced its therapeutic efficacy.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C10H7N3O4S
|
|---|---|
| Molecular Weight |
265.25
|
| Exact Mass |
265.02
|
| Elemental Analysis |
C, 45.28; H, 2.66; N, 15.84; O, 24.13; S, 12.09
|
| CAS # |
173903-47-4
|
| Related CAS # |
Tizoxanide-d4;1246817-56-0
|
| Appearance |
Solid powder
|
| SMILES |
O=C(NC1=NC=C([N+]([O-])=O)S1)C2=CC=CC=C2O
|
| InChi Key |
FDTZUTSGGSRHQF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H7N3O4S/c14-7-4-2-1-3-6(7)9(15)12-10-11-5-8(18-10)13(16)17/h1-5,14H,(H,11,12,15)
|
| Chemical Name |
2-hydroxy-N-(5-nitrothiazol-2-yl)benzamide
|
| Synonyms |
NSC-697856; NSC697856; NSC697856; Tizoxanide; Desacetylnitazoxanide; Desacetyl-nitazoxanide;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~94.25 mM)
Ethanol : < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (18.85 mM) in 15% Cremophor EL + 85% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication (<60°C).
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 15% Cremophor EL+85% Saline: 5 mg/mL (18.85 mM) View More
Solubility in Formulation 3: 5 mg/mL (18.85 mM) in 17% Polyethylene glycol 12-hydroxystearate in Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7700 mL | 18.8501 mL | 37.7003 mL | |
| 5 mM | 0.7540 mL | 3.7700 mL | 7.5401 mL | |
| 10 mM | 0.3770 mL | 1.8850 mL | 3.7700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Forward genetic screen for identification of NTZ resistant worm mutants.Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
|---|
Dose response curves ofC. elegansmutants resistant to other classes of drugs to NTZ in a six day lethality assay.Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
Combination of NTZ with albendazole (ALB) and pyrantel (PYR).Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
Ivermectin (IVM) susceptibility of the two NTZ resistant mutants identified in forward genetic screens at 44–45 hours.Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
|---|
Effect of NTZ onC. elegansN2 wild-type nematodes.Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
